Eton Pharmaceuticals Delivers Record Growth Amid Investor Caution

Eton Pharmaceuticals is reporting exceptional financial performance with quarterly revenue more than doubling and product demand surging dramatically. The company has responded by raising its forward guidance, yet market participants appear to be hesitating rather than celebrating these results. This disconnect between strong fundamentals and investor sentiment presents a puzzle for the specialty pharmaceutical company focused on rare diseases.

The company’s second quarter 2025 financial results demonstrated remarkable momentum across Read more...